AB Science's Masitinib Shows 2x Survival Boost in ALS Patients
Event summary
- Masitinib treatment achieved a 5-year survival rate of 42.3% in ALS patients, double historical benchmarks.
- 52.9% survival rate observed in patients without prior complete loss of functionality, emphasizing early intervention.
- 49% of long-term survivors maintained quality of life without mechanical assistance.
- Median overall survival of 121 months in masitinib-treated survivors vs. 42 months predicted by ENCALS model.
The big picture
AB Science's masitinib demonstrates a substantial survival advantage in ALS patients, challenging historical benchmarks and highlighting the potential of targeting microglial and mast cell activity. The findings suggest a mechanistic pathway that could enable more precise patient selection, a critical factor in the competitive ALS treatment landscape. The upcoming AB23005 study will be pivotal in confirming these results and positioning masitinib as a potential standard of care.
What we're watching
- Clinical Validation
- Whether confirmatory evidence will translate these findings into clinical practice.
- Biomarker Development
- The pace at which a plasma biomarker for masitinib's effect on pro-inflammatory microglia will be validated.
- Patient Stratification
- How AB Science will leverage the identified subpopulation to refine patient selection for masitinib.